Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis

Genetics in Medicine

Volumn 17, Issue 10, 2015, Pages 789-795

  Pashayan, Nora ^a   Duffy, Stephen W ^b   Neal, David E ^c   Hamdy, Freddie C ^d   Donovan, Jenny L ^e   Martin, Richard M ^e   Harrington, Patricia ^f   Benlloch, Sara ^f   Amin Al Olama, Ali ^f   Shah, Mitul ^g   Kote Jarai, Zsofia ^h   Easton, Douglas F ^f   Eeles, Rosalind ^h   Pharoah, Paul D ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

overdiagnosis; polygenic risk; prostate cancer; riskstratified screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; GENERAL PATHOLOGICAL PARAMETERS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN SOJOURN TIME; OVERDIAGNOSIS; POLYGENIC RISK; PREVALENCE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TIME; ALGORITHM; BIOLOGICAL MODEL; CANCER GRADING; CANCER STAGING; EARLY CANCER DIAGNOSIS; GENE LOCUS; GENETICS; HEALTH SERVICE; MIDDLE AGED; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS; STATISTICAL MODEL; UNITED KINGDOM;

AGED; ALGORITHMS; BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; GENETIC LOCI; GENETIC TESTING; HUMANS; MALE; MEDICAL OVERUSE; MIDDLE AGED; MODELS, GENETIC; MODELS, STATISTICAL; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RISK; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

EID: 84942994349     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.192     Document Type: Article

References (23)

1. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134
2. Andriole GL, Crawford ED, Grubb RL 3rd, et al.; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012; 104: 125-132
3. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-2035
4. Burton H, Sagoo GS, Pharoah P, Zimmern RL. Time to revisit Geoffrey Rose: strategies for prevention in the genomic era? Ital J Public Health 2012; 9: e8665-1-e8665-9
5. Pashayan N, Duffy SW, Chowdhury S, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011; 104: 1656-1663
6. Eeles R, Goh C, Castro E, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014; 11: 18-31
7. Eeles RA, Olama AA, Benlloch S, et al.; COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45: 385-91, 391e1
8. Bahcall O.Risk prediction and population screening for breast, ovarian and prostate cancers. Nat Genet 2013. http://www.nature.com/icogs/primer/riskprediction-And-population-screening-for-breast-ovarian-And-prostate-cancers/
9. Donovan J, Hamdy F, Neal D, et al.; ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-88
10. Lane JA, Donovan JL, Davis M, et al.; ProtecT study group. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014; 15: 1109-1118
11. Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: 9-15
12. Wang J, Lin M, Crenshaw A, et al. High-Throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays. BMC Genomics 2009; 10: 561
13. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-36
14. Pashayan N, Duffy SW, Pharoah P, et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 2009; 100: 1198-1204
15. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-919
16. MacInnis RJ, Antoniou AC, Eeles RA, et al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol 2010; 34: 42-50
17. Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol 2013; 10: 38-48
18. Xu J, Isaacs SD, Sun J, et al. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008; 14: 5819-5824
19. Bao BY, Pao JB, Lin VC, et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta 2010; 411: 1232-1237
20. Hakama M, Auvinen A, Day NE, Miller AB. Sensitivity in cancer screening. J Med Screen 2007; 14: 174-177
21. Finne P, Fallah M, Hakama M, et al. Lead-Time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer 2010; 46: 3102-3108
22. Auvinen A, Määttänen L, Stenman UH, et al. Lead-Time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279-285
23. Pashayan N, Guo Q, Pharoah PD. Personalized screening for cancers: should we consider polygenic profiling? Per Med 2013; 10: 511-513